💨 Abstract

The author, diagnosed with secondary breast cancer in 2022, expresses frustration over the NHS's rejection of a potentially life-extending drug, Enhertu. Initially diagnosed with primary breast cancer in 2020, she faced delays and errors in treatment due to COVID-19. Despite her advocacy and the drug's approval in Scotland and other European countries, she and others in England, Wales, and Northern Ireland are denied access.

Courtesy: Sophie Blake